References
- Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011;29(32):4294-301
- Eggertson L. Provinces weighing HPV vaccination of boys. Can Med Assoc J 2012;184(5):E250-1
- Johnson-Obaseki S, McDonald JT, Corsten M, Rourke R. Head and neck cancer in Canada: trends 1992 to 2007. Otolaryng Head Neck 2012;147(1):74-8
- Gotay CC. Cancer prevention: major initiatives and looking into the future. Expert Rev Pharmacoecon Outcomes Res 2010;10(2):143-54
- National Cancer Institute. General information about oropharyngeal cancer. National Institutes of Health (2014). Available from: www.cancer.gov/cancertopics/pdq/treatment/oropharyngeal/Patient/page1
- Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. NEJM 2010;363(1):24-35
- Kjaer SK, Sigurdsson K, Iversen O-E, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res 2009;2(10):868-78
- Donovan B, Franklin N, Guy R, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011;11(1):39-44
- Chesson HW, Ekwueme DU, Saraiya M, et al. The cost-effectiveness of male HPV vaccination in the United States. Vaccine 2011;29(46):8443-50
- The Society of Obstetricians and Gynaecologists of Canada. HPV immunization strategies by province. (2014). Available from: www.hpvinfo.ca/teens/hpv-vaccination/hpv-immunization-strategies-by-province/
- Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. NEJM 2011;364(5):401-11
- Centers for Disease Control and Prevention. ACIP recommends all 11-12 year-old males get vaccinated against HPV. Centers for Disease Control and Prevention (2011). Available from: www.cdc.gov/media/releases/2011/t1025_hpv_12yroldvaccine.html
- Public Health Agency of Canada. Update on human papillomavirus (HPV) vaccines. (2012). Available from: www.phac-aspc.gc.ca/publicat/ccdr-rmtc/12vol38/acs-dcc-1/index-eng.php#a5
- Ikura S, Yiu V, Sullivan T. Should HPV vaccination programs be expanded to boys? Healthy Debate (2014). Available from: http://healthydebate.ca/2014/03/topic/managing-chronic-diseases/hpv-vaccine-boys
- Fine P, Eames K, Heymann DL. “Herd immunity”: a rough guide. Clin Infect Dis 2011;52(7):911-16
- Van de Velde N, Brisson M, Boily M-C. Understanding differences in predictions of HPV vaccine effectiveness: a comparative model-based analysis. Vaccine 2010;28(33):5473-84
- Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 2009;339:b3884
- Elbasha EH, Dasbach EJ. Impact of vaccinating boys and men against HPV in the United States. Vaccine 2010;28(42):6858-67
- Bresse X, Goergen C, Prager B, Joura E. Universal vaccination with the quadrivalent HPV vaccine in Austria: impact on virus circulation, public health and cost-effectiveness analysis. Expert Rev Pharmacoecon Outcomes Res 2014;14(2):269-81
- Graham D, Isaranuwatchai W, Habbous S, et al. A preliminary cost-effectiveness analysis of human papillomavirus vaccination in males for the prevention of oropharyngeal cancer. Presented at: ASCO Annual Meeting. 2013
- La Torre G, de Waure C, Chiaradia G, et al. Guidance for future HTA applications to vaccines: the HPV lesson. Hum Vaccin 2011;7(9):900-4